Vitiligo Clinical Trials: How to Find and Join a Study

Clinical trials are how new vitiligo treatments get proven and eventually approved. For patients, they also represent an opportunity: access to treatments that may be more advanced than what is currently available commercially, at no drug cost, under close medical supervision. Vitiligo is an active area of clinical research right now — trials of oral JAK inhibitors, new topical formulations, and novel immunological approaches are ongoing.

This guide explains how to find active trials, understand eligibility, and make an informed decision about participation.

Why vitiligo is an active research area

The FDA approval of Opzelura (ruxolitinib cream) in 2022 — the first specifically approved vitiligo treatment — opened the door for accelerated trial activity. Several oral JAK inhibitors, including upadacitinib and baricitinib, have phase 3 trial data emerging. Combination approaches, longer-acting formulations, and immunological targets beyond JAK inhibition are all in earlier-stage trials.

This means the next few years will bring multiple new treatment options. Trials currently recruiting are testing treatments that may be approved within two to five years.

How to find active vitiligo trials

ClinicalTrials.gov

The US National Institutes of Health maintains ClinicalTrials.gov, the most comprehensive global registry of clinical trials. Searching for vitiligo trials:

Go to clinicaltrials.gov
Search for “vitiligo” in the condition field
Filter by Status: Recruiting to see only trials currently enrolling patients
Filter by location to find trials near you (or specify willingness to travel)
Filter by Phase — Phase 2 and 3 trials are generally more advanced and more likely to offer meaningful treatment; Phase 1 studies are primarily safety-focused

Each trial listing includes the sponsor, locations, eligibility criteria, what is being tested, and contact details.

EU Clinical Trials Register

For European patients: the EU Clinical Trials Register (euclinicaltrials.eu) covers EU-regulated trials, including some not listed on ClinicalTrials.gov.

Pharmaceutical company websites

Major pharmaceutical companies (Incyte, AbbVie, Eli Lilly, Pfizer, Arena Pharmaceuticals) run their own trial finder tools on their websites. If you know which drug pipeline you are interested in, searching directly on the sponsor’s site can identify trials that may not appear prominently on clinicaltrials.gov searches.

Patient advocacy organisations

The Global Vitiligo Foundation and similar organisations often maintain updated lists of active trials and can connect patients with trial coordinators. These are worth contacting if self-navigation of clinical trial databases feels overwhelming.

Understanding eligibility criteria

Every trial has inclusion and exclusion criteria. Common requirements for vitiligo trials:

Typical inclusion criteria:

Diagnosis of non-segmental (generalised) vitiligo (some trials also include segmental)
Minimum body surface area affected (often ≥0.5% to qualify as measurable disease)
Minimum age (many trials require 18+, though some include 12+)
Active disease (some trials want evidence of spread in the past 12 months)

Common exclusion criteria:

Current use of competing vitiligo treatments (must discontinue and wash out before joining)
Pregnancy or breastfeeding
Certain other medical conditions (active infections, immunodeficiency, certain malignancies)
Recent use of systemic immunosuppressants
Segmental vitiligo (for trials specifically studying non-segmental disease)

Exclusion criteria exist for patient safety and scientific validity — they are not arbitrary. If you are excluded from one trial, you may be eligible for another with different criteria.

What participation actually involves

Trial participation is more demanding than standard care, but also more comprehensive. What to expect:

More frequent clinic visits: Phase 3 trials often require visits every four to eight weeks for assessments, blood tests, and photography. This is manageable for many patients but requires planning around work and travel.

Randomisation: In placebo-controlled trials, some participants receive placebo rather than the active drug. This is standard scientific practice that enables comparison. Trials typically have crossover options (patients on placebo switch to active drug after a set period) or open-label extension phases where all participants receive the drug.

No drug cost: The investigational treatment is provided at no cost. You may also receive reimbursement for travel and visit costs — ask the trial coordinator about this.

Close monitoring: More frequent safety monitoring than standard care. Blood tests, physical exams, and standardised photography at each visit. This level of monitoring is actually a benefit — abnormalities are caught early.

Exit option: You can withdraw from a trial at any point without penalty or effect on your standard medical care.

Questions to ask before enrolling

When you contact a trial coordinator or attend a pre-screening visit:

What is the randomisation ratio? (What are the odds of receiving placebo vs active drug?)
Is there an open-label extension? (Can I switch to active drug if randomised to placebo?)
What happens at the end of the trial — can I continue treatment?
What monitoring is included, and what will I need to do between visits?
What are the known side effects of the investigational treatment?
How will this affect my ability to start or continue other vitiligo treatments?

Is participation appropriate for you?

Clinical trials are worth considering if:

You have tried standard treatments without adequate response
You are interested in cutting-edge treatments before they become widely available
You can manage the visit frequency and geographic requirements
You are willing to accept the possibility of randomisation to placebo (in placebo-controlled trials)

They may be less appropriate if:

You are currently responding well to an approved treatment
The visit schedule is incompatible with work or family commitments
The geographic distance to the trial site is prohibitive

The vitiligo treatment options comparison gives context on what is currently approved and available if you are comparing trial participation against standard treatment options.